May 30, 2024 – Theralase releases the Company’s unaudited interim consolidated 1Q2024 Financial Statements

May 2, 2024 – Theralase expands its clinical team with the hiring of two Clinical Research Associates.

April 5th, 2024, Theralase® granted Canadian patent for a new cancer vaccine titled, “Vaccine Containing Cancer Cells Inactivated by Photodynamic Treatment with Metal-Based Coordination Complexes and Immunotherapy Method Using Same”.

March 27, 2024 – Theralase released the Company’s audited annual consolidated 2023 financial statements (“Financial Statements”).

V.TLT | March 26th, 2024 Toronto, Ontario – March 26th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, announced today that it is hosting Advisory Board meetings to present the latest Study II interim clinical data to its Principal Investigators (“PIs”) at the Canadian Urological Association (“CUA”) Bladder Cancer Forum and the American Urology Association (“AUA”), respectively. Study II is a Phase II clinical study that provides a Study Procedure (Study Drug activated by a Study Device) for patients diagnosed with Bacillus Calmette Guerin (“BCG”)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In-Situ (“CIS”). An advisory board meeting is scheduled to take place on April 12, 2024, during the Bladder Cancer Forum 2024 located in … Read More

V.TLT | February 8th, 2024 Toronto, Ontario – February 8th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (“PDCs“) for the safe and effective destruction of various cancers, bacteria and viruses is pleased to announce that Dr. Michael Jewett has joined Theralase®, in the role of an independent consultant, to assist the Company in the completion of enrollment of patients in the Phase II Bacillus Calmette-Guérin (“BCG”)-Unresponsive Non Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In-Situ (“CIS”) clinical study (“Study II”). Under the terms of the consulting agreement, Dr. Jewett will be responsible for working with existing clinical study sites and helping to onboard new clinical study sites to allow Theralase® to complete enrollment and provide the primary study treatment to all 100 patients in Study II, preferably by December 31, … Read More

Toronto, Ontario – November 29th, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (“PDCs”) for the safe and effective destruction of various cancers, bacteria and viruses has released the Company’s 3Q2023 unaudited condensed interim consolidated Financial Statements (“Financial Statements”). Financial Summary: For the nine-month period ended September 30th: 1 Other represents foreign exchange, interest accretion on lease liabilities and / or interest income Financial Highlights for the Nine-Month Period Ended September 30th, 2023: Total revenue decreased 13%, year over year. Cost of sales for the nine-month period ended September 30th, 2023 was $363,882 or 51% of revenue resulting in a gross margin of $342,813 or 49% of revenue.  In comparison, the cost of sales for the same period in 2022 was $389,232 or 48% of revenue resulting … Read More

Toronto, Ontario – October 23, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (“PDCs”) for the safe and effective destruction of various cancers, bacteria and viruses. Theralase® is pleased to announce that it has entered into an agreement with Research Capital Corporation as the sole agent and sole bookrunner (“RCC” or “Agent”) on a “best efforts” agency basis, brokered offering (“Offering”) of units of the Company (“Units”) at a price of C$0.22 per Unit. The Offering will be subject to a minimum of 15,909,091 Units and a maximum of 24,090,910 Units at a price of C$0.22 per Unit for aggregate gross proceeds to the Company of a minimum C$3,500,000 and up to a maximum of C$5,300,000.  Each Unit consists of one (1) common share of the Company (“Common Share”) and one (1) Common Share purchase warrant (“Warrant”). Each Warrant will entitle … Read More

Theralase®’s Latest Clinical Data Demonstrates 65% of Patients Treated with Theralase®’s Anti-Cancer Therapy Achieved a Complete Response Toronto, Ontario – October 16, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF) is a clinical stage pharmaceutical company dedicated to the research and development of light or radiation activated Photo Dynamic Compounds (“PDCs”) for the safe and effective destruction of various cancers, bacteria and viruses. Theralase® is providing an update to its Phase II Bacillus Calmette Guérin (“BCG”)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In-Situ (“CIS”) (with or without resected Ta / T1 papillary disease) clinical study (“Study II”). To date, Theralase® has enrolled and provided the primary Study II Treatment for 62 patients. The Study II Endpoints have been defined as: Primary: Efficacy – Defined as Complete Response (“CR”) rate at any point in time (CR is defined as at least one of the following: Secondary: Duration of CR – Defined as 12 months post initial CR assessment Tertiary: Safety … Read More